期刊文献+

与时俱进,不断丰富病理学科的内涵 被引量:1

原文传递
导出
摘要 病理学是一门重要的基础学科,又是一门十分重要的临床医学学科。她从诞生之日起就不断地汲取基础科学和医学的成果,使自己不断发展壮大,逐渐形成了以研究组织病理改变为主的病理形态学,并在疾病诊断中占据了决定性的地位。随着免疫学理论与技术的进步和电镜的问世,病理学又有了免疫病理学及免疫组织化学及超微病理学作为疾病病理诊断的重要手段,使我们对疾病的诊断有了长足的进步。分子生物学、遗传学以及分子遗传学的发展进一步给病理学科带来了新的机遇,使我们有条件把相关学科的科学成就应用到病理学研究及应用领域。正如新出版的WHO肿瘤分类系列,就用病理学和遗传学的醒目标题来强调现今的病理学家进行肿瘤的病理分类时不仅应注意形态学,还应充分重视每种肿瘤的遗传学特性。
作者 陈杰 霍临明
出处 《中华病理学杂志》 CAS CSCD 北大核心 2008年第2期73-74,共2页 Chinese Journal of Pathology
作者简介 陈杰,E-mail:xhblk@163.com
  • 相关文献

参考文献9

二级参考文献46

  • 1郑杰.促进我国病理学科的现代化建设[J].中华病理学杂志,2005,34(8):471-472. 被引量:21
  • 2曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量:65
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:166
  • 4陆锦标,朱雄增.弥漫大B细胞淋巴瘤基因表达谱的研究进展[J].中华病理学杂志,2006,35(11):684-686. 被引量:12
  • 5Normanno N,De Luca A,Bianco C,et al.Epidermal growth factor receptor (EGFR) signaling in cancer.Gene,2006,366:2-16.
  • 6Normanno N,Bianco C,De Luca A,et al.Target-based agents against ErbB receptors and their ligands:a novel approach to cancer treatment.Endocr Relat Cancer,2003,10:1-21.
  • 7Lal P,Salazar PA,ladanyi M,et al.Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinoma without HER2/neu gene amplification.J Mol Diagn,2003,5:155-159.
  • 8Fornier M,Risio M,Van Poznak C,et al.HER2 testing and correlation with efficacy of trastuzumab therapy.Oncology,2002,16:1340-1348.
  • 9Saez A,Andreu FJ,Segui MA,et al.HER-2 gene amplification by chromogenic in situ hybridization (CISH) compared with fluorescence in situ hybridization (FISH) in breast cancer.A study of two hundred cases.Breast,2006,15:519-527.
  • 10Peiro G,Mayr D,Hillemanns P,et al.Analysis of HER2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization.Correlation with fluorescence in situ hybridization,HER-2/neu,p53 and Ki-67 protein expression,and outcome.Mod Pathol,2004,17:277-287.

共引文献80

同被引文献16

  • 1汪世容,关柏林.转化医学:B2B医疗新模式.文汇报,2008-11-08(7).
  • 2Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol, 2008, 26(30) :4869-4874.
  • 3Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008 : 233-237.
  • 4Feder JN, Gnirke A, Thomas W, et al. A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet, 1996, 13(4):399-408.
  • 5Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer, 2006, 42 ( 8 ) : 1093-1103.
  • 6Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase Ⅲ trial in non-small-cell lung cancer. J Clin Oncol, 2007, 25(19):2747-2754.
  • 7Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 2006, 355(10) :983-991.
  • 8Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455 (7216) : 1061-1068.
  • 9吕亚莉,钟梅,刘琳,韦立新,赵坡.乳腺癌17号染色体多体的临床病理意义[J].中华病理学杂志,2008,37(2):88-91. 被引量:6
  • 10徐方平,刘艳辉,庄恒国.肺腺癌分子分型的研究进展[J].中华病理学杂志,2008,37(3):190-192. 被引量:4

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部